I would note it specifies “cancer types” and not merely “sub types”, if correct we will get to understand the breadth of Zantrene’s super powers.
This will help convey value to Pharma and the market. I understand as a general rule of thumb most drugs work on single indication / targets. So if we improve on this things will be looking good!
Ann: December 2022 Preclinical & Clinical Programs Update, page-11
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.73 |
Change
0.030(1.76%) |
Mkt cap ! $296.3M | |||
| Open | High | Low | Value | Volume |
| $1.74 | $1.75 | $1.70 | $123.1K | 71.34K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1621 | $1.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.73 | 1600 | 1 |
View Market Depth
| Last trade - 12.29pm 25/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |